{
    "clinical_study": {
        "@rank": "48838", 
        "brief_summary": {
            "textblock": "OBJECTIVES:\n\n      I. Determine the safety of isotretinoin in patients with recessive dystrophic epidermolysis\n      bullosa."
        }, 
        "brief_title": "Phase I Study of Isotretinoin in Patients With Recessive Dystrophic Epidermolysis Bullosa", 
        "condition": "Epidermolysis Bullosa", 
        "condition_browse": {
            "mesh_term": [
                "Epidermolysis Bullosa", 
                "Epidermolysis Bullosa Dystrophica"
            ]
        }, 
        "detailed_description": {
            "textblock": "PROTOCOL OUTLINE:\n\n      Patients receive oral isotretinoin daily for 8 months in the absence of disease progression\n      or unacceptable toxicity."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "PROTOCOL ENTRY CRITERIA:\n\n        --Disease Characteristics--\n\n          -  Diagnosis of recessive dystrophic epidermolysis bullosa (RDEB) RDEB Hallopeau-Siemens\n             OR RDEB non-Hallopeau-Siemens\n\n          -  Concurrent enrollment in the National Epidermolysis Bullosa Registry\n\n          -  No regional or distant metastasis in patients with previous or concurrent squamous\n             cell carcinoma\n\n        --Patient Characteristics--\n\n          -  Hepatic: No clinically significant hypertriglyceridemia No clinically significant\n             hepatic dysfunction\n\n          -  Renal: No clinically significant renal dysfunction\n\n          -  Other: Not pregnant or nursing Negative pregnancy test Fertile patients must use\n             effective contraception"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "15 Years"
        }, 
        "enrollment": "20", 
        "firstreceived_date": "April 10, 2001", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00014729", 
            "org_study_id": "199/15738", 
            "secondary_id": "UNCCH-FDR001796"
        }, 
        "intervention": {
            "intervention_name": "isotretinoin", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Isotretinoin"
        }, 
        "keyword": [
            "dermatologic disorders", 
            "epidermolysis bullosa", 
            "genetic diseases and dysmorphic syndromes", 
            "rare disease"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "overall_official": {
            "affiliation": "University of North Carolina", 
            "last_name": "Jo-David Fine", 
            "role": "Study Chair"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 1", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00014729"
        }, 
        "source": "FDA Office of Orphan Products Development", 
        "sponsors": {
            "collaborator": {
                "agency": "University of North Carolina", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "FDA Office of Orphan Products Development", 
                "agency_class": "U.S. Fed"
            }
        }, 
        "start_date": "October 2000", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2001"
    }, 
    "geocoordinates": {}
}